BioXcel Q4 net loss narrows to $22.3M; cash runs only to mid-2024; FDA requires more TRANQUILITY data

BioXcel Therapeutics, Inc.

Net loss $22.3M Q4 2023 vs $54.8M Q4 2022; full-year net loss $179.0M vs $165.8M.
Cash and equivalents $65.2M at Dec 31, 2023, expected to fund operations only through mid-2024.
FDA requires additional Phase 3 efficacy/safety data for BXCL501 in care facilities for Alzheimer's agitation (TRANQUILITY); at-home trial re-evaluated.
SERENITY program: FDA meeting supports Phase 3 trial amendment for at-home use of 120 mcg BXCL501 for bipolar/schizophrenia agitation.
Initiated formal process to assess strategic options for OnkosXcel Therapeutics subsidiary.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BioXcel Therapeutics, Inc. reported the fourth quarter and full year 2023 results: revenue Net revenue from IGALMI was $376,000 for the fourth quarter of 2023.

Period: the fourth quarter and full year 2023
Revenue: Net revenue from IGALMI was $376,000 for the fourth quarter of 2023
Result: reported results

Exact text from the filing

Net revenue from IGALMI was $376,000 for the fourth quarter of 2023, compared to $238,000 for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

BioXcel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-033247

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.